ClinicalTrials.gg
SuspendedNCT04280692CHMI-TransModUpdated May 23, 2024

Controlled Human Malaria Infection Transmission Model - Phase A

A Phase 1/2 interventional study of PfSPZ Challenge and Sulfadoxine-Pyrimethamine in Malaria,Falciparum, sponsored by University of Oxford. Suspended at 1 site in Kenya. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-23.

Sponsored by University of Oxford · Phase 1/2, Interventional, and Basic science

How we know

Why this study was suspended
Study halted prematurely due to US FDA clinical hold on PfSPZ Challenge

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing PfSPZ Challenge in Malaria, Falciparum — 1 open to participants now, 1 under way, none of them phase 3. PfSPZ Challenge · Malaria, Falciparum.

Enrollment
4th of 12
44 · median 31
Started
2022
the only one that year
Phase 1/2
Only one
of the 12
Registered
11th of 12
by date
Lead sponsor
1 of 12
University of Oxford

Among the 12 studies testing PfSPZ Challenge in Malaria, Falciparum, this one is the 4th largest by enrollment, is the only one that started in 2022, is the only one in phase 1/2, and was the 11th registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

1 of the 12 studies testing PfSPZ Challenge in Malaria, Falciparum is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About PfSPZ Challenge

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing PfSPZ Challenge in Malaria, Falciparum, or all of them as a file.
02

Study summary

This is to develop a model to test the efficacy of vaccines and/or drugs designed to block transmission of malaria to mosquitoes and to identify the targets of transmission-blocking immunity to malaria.

Read the detailed description

Malaria is a disease of major public health importance. The only vaccine available is partially effective and targets the pre-erythrocytic stages of the life cycle. Thus, there is a need to identify other potential vaccine targets as well as to develop models to test vaccine efficacy, especially that of transmission-blocking vaccines. Controlled human malaria infection (CHMI) has been shown to be an important tool for the assessment of the efficacy of novel malaria vaccines and drugs. CHMI also allows for the evaluation of immunity to malaria and monitoring of parasite growth rates in vivo. This is particularly useful in individuals from endemic areas with varying levels of exposure and immunity to malaria. Thus, CHMI in individuals with prior exposure to malaria has potential to accelerate malaria vaccine development. In this study, the aim is to use CHMI in semi-immune adults to develop a model to assess transmissibility of malaria infection to mosquitoes, to study immune responses that are directed against sexual stages that might block transmission, and as a platform to test vaccines. To achieve this, the study will be carried out in two phases A (N=45 participants) and B (N=60 participants) over a period of 4-6months. Parasite dose will be varied in individuals enrolled for CHMI and use of low-doses of anti-malarial drugs to promote the production of gametocytes in vivo (Phase A) and demonstrate transmissibility in mosquito feeding assays (Phase B). Thus, the main outcomes of the study will be: (1) optimisation of sporozoite dose for infections success in individuals with moderate-high malaria exposure; (2) use of sub-curative anti-malaria treatment for induction of gametocytes; and (3) infection of mosquitoes in mosquito feeding assays by induced gametocytes. To achieve this, up to 250 semi-immune adults will be recruited from known areas of malaria endemicity in Kenya with varying exposure to malaria undergo screening procedures after informed consent to enrol 105 individuals to conduct CHMI studies with serial quantitative polymerase chain reaction (PCR) to measure asexual parasite growth and induction of transmission stages in vivo. In addition, comprehensively characterize immunity and identify targets in relation to function assessed by various laboratory assays.

03

Conditions studied

  • Malaria,Falciparum

Browse trials for

Keywords

  • PfSPZ
  • Kenya
  • Gametocytes
  • Transmission
  • CHMI
  • Challenge
  • semi-immune adults
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adults aged 18 to 45 years.
  2. Able and willing (in the Investigator's opinion) to comply with all study requirements.
  3. .
  4. Use of effective method of for duration of study (women only). We will ask the female volunteers to come with their family planning records to verify. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly, in accordance with the product label. Examples of these include: combined oral contraceptives; injectable progestogen; implants of etenogestrel or levonorgestrel; intrauterine device or intrauterine system; male partner sterilisation at least 6 months prior to the female subject's entry into the study, and the relationship is monogamous; male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository); and male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).

Exclusion criteria

Exclusion Criteria:

  1. Body weight of less than 50kg or (BMI) less than 18 or greater than 25 kg/m2 at screening.
  2. Use of systemic antibiotics with known antimalarial activity within 30 days of administration of PfSPZ Challenge (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin).
  3. Receipt of an product in the 30 days preceding enrolment, or planned receipt during the study period.
  4. Current participation in another clinical trial or recent participation within 12 weeks of enrolment.
  5. Prior receipt of an investigational malaria vaccine.
  6. Any confirmed or suspected or immunodeficient state, including infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical are allowed). This will also include Virus (HBV) and Virus (HCV) positivity.
  7. Use of immunoglobulins or blood products within 3 months prior to enrolment.
  8. Any serious medical condition reported or identified during screening that increases the risk of CHMI.
  9. Any abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination.
  10. Women only; pregnancy, or an intention to become pregnant during the duration of the study.
  11. Sickle cell trait or disease.
  12. History of drug or alcohol abuse.
  13. Known to or for use of artemether-lumefantrine, chloroquine, piperaquine, primaquine, sulfadoxine-pyrimethamine, or history of severe (allergic) reactions to mosquito bites.
  14. Confirmed gametocyte positivity at screening and/or a day before challenge
  15. Confirmed parasite positive by PCR a day before challenge i.e. at C-1. Exclusion Criterion on Day of Challenge

    • Acute disease, defined as moderate or severe illness with or without fever (temperature >37.5 degrees Celcius).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Group 1: PfSPZ 6,400

    Group 1 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 6,400 sporozoites. Group 1 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg). Group 1 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)

    Biological: PfSPZ Challenge · Drug: Sulfadoxine-Pyrimethamine · Drug: Piperaquine · Drug: Artemether lumefantrine · Drug: Primaquine

  • Experimental
    Group 1: PfSPZ 12,800

    Group 2 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 12,800 sporozoites Group 2 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg). Group 2 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)

    Biological: PfSPZ Challenge · Drug: Sulfadoxine-Pyrimethamine · Drug: Piperaquine · Drug: Artemether lumefantrine · Drug: Primaquine

  • Experimental
    Group 3: PfSPZ 25,600

    Group 3 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 25,600 sporozoites Group 3 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg). Group 3 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)

    Biological: PfSPZ Challenge · Drug: Sulfadoxine-Pyrimethamine · Drug: Piperaquine · Drug: Artemether lumefantrine · Drug: Primaquine

Interventions

  • BiologicalPfSPZ Challenge

    Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites

    Also known as: NF54 Plasmodium falciparum malaria challenge

  • DrugSulfadoxine-Pyrimethamine

    Sub-curative 500mg/25mg single dose regimen

    Also known as: Fansidar

  • Sub-curative 480mg single dose regimen

    Also known as: Piperaquine Phosphate

  • DrugArtemether lumefantrine

    Three day curative regimen 20mg/120mg

    Also known as: Coartem

  • Single low dose regimen 0.25 mg base/kg

06

What researchers measure

Primary outcomes

  1. Safety and optimisation of sporozoite dose for infections success in individuals with moderate-high malaria exposure

    Magnitude and frequency of adverse events in the study groups

    Time frame: Up to 42 days post infection with PfSPZ challenge

  2. Prevalence of gametocytes

    Prevalence of gametocytes as determined by qRT-PCR

    Time frame: Up to 42 days post infection with PfSPZ challenge

Secondary outcomes

  1. Use of sub-curative anti-malaria treatment for induction of gametocytes

    Density of gametocytes as measured by qRT-PCR

    Time frame: Up to 42 days post infection with PfSPZ challenge

  2. Peak density and time point of gametocytaemia

    Peak density and peak time point of gametocytes by drug-regimen and determine the area under the curve of density over time

    Time frame: Up to 42 days post infection with PfSPZ challenge

07

Study locations

1 site
  • KEMRI-Wellcome Trust Research Programme
    Kilifi, 80108, Kenya
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Dec 2025, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2020
First posted
Feb 21, 2020
StartActual
Aug 22, 2022
Primary completionEst.
Dec 2025
CompletionEst.
Aug 2026
Last update
May 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04280692
Collaborators
KEMRI-Wellcome Trust Collaborative Research Program, Sanaria Inc., Kenya Medical Research Institute
Responsible party
Sponsor
First posted
Feb 21, 2020
Start date
Aug 22, 2022
Primary completion
Dec 2025 (estimated)
Completion
Aug 2026 (estimated)
Last update
May 23, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PfSPZ Challenge · Piperaquine · Primaquine

Start the discussion